Skip to main content

Table 2 Background characteristics according to HCV RNA positivity

From: Change in hepatitis C virus positivity among needle-stick injury source patients: a 10-year experience in a Japanese tertiary hospital

Variables Between 2009 and 2014
(n = 102)
Between 2015 and 2019
(n = 48)
HCV-RNA
Positive
(n = 78)
HCV-RNA
Negative
(n = 24)
p-value HCV-RNA
Positive
(n = 23)
HCV-RNA
Negative
(n = 25)
p-value
Age (years) 71.7 ± 10.6 63.8 ± 14.5 0.0122* 71.4 ± 8.8 69.4 ± 13.5 0.8123
Gender, male – no. (%, 95CI) 44 (56.4, 45.4–66.9) 17 (70.8, 50.8–85.1) 0.2412 11 (47.8, 29.2–67.0) 16 (64.0, 44.5–79.8) 0.3830
HCV-Ab titera 9.8 ± 0.6 6.9 ± 2.9 <  0.0001* 10.0 ± 0.1 7.3 ± 3.4 0.0006*
Department, LDs – no. (%, 95CI) 46 (59.0, 47.9–69.2) 8 (33.3, 18.0–53.3) 0.0358* 14 (60.9, 40.8–77.8) 7 (28.0, 14.3–47.6) 0.0405*
Antiviral therapyb
 -Interferon, Yes – no. (%, 95CI) 27 in 75
(36.0, 26.1–47.3)
12 in 21
(57.1, 36.5–75.5)
0.1302 7 in 22
(31.8, 16.4–52.7)
10 in 23
(43.5, 25.6–63.2)
0.5420
 -DAAs, Yes – no. (%, 95CI) 2 in 22
(9.1, 2.5–27.8)
9 in 23
(39.1, 22.2–59.2)
0.0351*
  1. Values are expressed as means ± SD unless otherwise stated
  2. HCV hepatitis C virus, LDs liver disease-related departments, CI confidence interval
  3. aAbout HCV-Ab titer, between 2009 and 2014, 1 HCV RNA-negative patient had no result documented in the medical record
  4. bAbout histories of antiviral therapy, between 2009 and 2014, 3 HCV RNA-positive and HCV RNA-negative patients each had no treatment history documented in the medical record. Between 2015 and 2019, 1 HCV RNA-positive and 2 HCV RNA-negative patients had no treatment history documented in their medical record. In the era after DAAs, 2 HCV RNA-positive and HCV RNA-negative patients each were treated with both IFN-based therapies and DAAs. Total number of each column was provided if there was missing data
  5. *p < 0.05